Income Statement Tenaya Therapeutics, Inc.

Stocks

TNYA

US87990A1060

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 10:06:08 2026-07-16 am EDT			5-day change	1st Jan Change
0.8210 ^USD	-2.63%		-4.71%	+13.84%

Jun. 29	Tenaya Therapeutics, Inc. Announces Management Changes, Effective July 13, 2026	CI
Jun. 29	Tenaya Therapeutics, Inc. Announces Chief Financial Officer Changes, Effective July 13, 2026	CI

5358eb282e.6ZD7s9PYzu2IpzzKwdhkBXj4agbI5pU13idPEPRmshU.i_az_L-qr7u86FODhr0MUi2MW0Od3-UN5xJ_UboO4mSC5qvFhYGemMbJUw

Published financial data: TENAYA THERAPEUTICS, INC.

Annual

Quarterly

Halfyear

YTD

LTM

Fiscal Period: December	2021	2022	2023	2024	2025
Selling General & Admin Expenses, Total	18.41M	31.08M	33.16M	29.21M	24.72M
R&D Expenses	54.39M	94.54M	98.04M	86.74M	68.61M
Other Operating Expenses, Total	72.81M	126M	131M	116M	93.33M
Operating Income	-72.81M	-126M	-131M	-116M	-93.33M
Interest And Investment Income	108K	1.95M	7.06M	4.74M	2.68M
Net Interest Expenses	108K	1.95M	7.06M	4.74M	2.68M
Other Non Operating Income (Expenses)	38K	2K	53K	82K	52K
EBT, Excl. Unusual Items	-72.66M	-124M	-124M	-111M	-90.6M
Gain (Loss) On Sale Of Assets	-61K	-	-	-	-
Other Unusual Items	-	-	-	-	-
EBT, Incl. Unusual Items	-72.72M	-124M	-124M	-111M	-90.6M
Earnings From Continuing Operations	-72.72M	-124M	-124M	-111M	-90.6M
Net Income to Company	-72.72M	-124M	-124M	-111M	-90.6M
Net Income - (IS)	-72.72M	-124M	-124M	-111M	-90.6M
Net Income to Common Incl Extra Items	-72.72M	-124M	-124M	-111M	-90.6M
Net Income to Common Excl. Extra Items	-72.72M	-124M	-124M	-111M	-90.6M
Per Share Items
Net EPS - Basic	-4.1	-2.76	-1.68	-1.31	-0.59
Basic EPS - Continuing Operations	-4.1	-2.76	-1.68	-1.31	-0.59
Basic Weighted Average Shares Outstanding	17.73M	44.82M	73.79M	84.82M	153M
Net EPS - Diluted	-4.1	-2.76	-1.68	-1.31	-0.59
Diluted EPS - Continuing Operations	-4.1	-2.76	-1.68	-1.31	-0.59
Diluted Weighted Average Shares Outstanding	17.73M	44.82M	73.79M	84.82M	153M
Normalized Basic EPS	-2.56	-1.72	-1.05	-0.82	-0.37
Normalized Diluted EPS	-2.56	-1.72	-1.05	-0.82	-0.37
Supplemental Items
EBITDA	-69.84M	-119M	-123M	-107M	-84.9M
EBITA	-72.81M	-126M	-131M	-116M	-93.33M
EBIT	-72.81M	-126M	-131M	-116M	-93.33M
EBITDAR	-64.14M	-113M	-117M	-101M	-79.92M
Normalized Net Income	-45.41M	-77.29M	-77.55M	-69.46M	-56.62M
Supplemental Operating Expense Items
General and Administrative Expenses	18.41M	31.08M	33.16M	29.21M	24.72M
Research And Development Expense From Footnotes	54.39M	94.54M	98.04M	86.74M	68.61M
Net Rental Expense, Total	5.7M	5.88M	5.63M	6M	4.98M
Stock-Based Comp., R&D Exp. (Total)	1.18M	4.91M	7.04M	8.2M	6.82M
Stock-Based Comp., G&A Exp. (Total)	1.77M	6.55M	8.27M	8.3M	6.23M
Total Stock-Based Compensation	2.95M	11.47M	15.31M	16.5M	13.05M

Fiscal Period: December	2021	2022	2023	2024	2025
Assets
Cash And Equivalents	38.13M	95.27M	45.68M	4.32M	101M
Short Term Investments	213M	91.26M	58.96M	57.12M	-
Total Cash And Short Term Investments	251M	187M	105M	61.45M	101M
Prepaid Expenses	4.06M	5.23M	5.78M	5.09M	4.01M
Other Current Assets, Total	-	2M	1.16M	842K	1.02M
Total Current Assets	255M	194M	112M	67.38M	106M
Gross Property Plant And Equipment	64.13M	78.37M	77.6M	80.04M	77.02M
Accumulated Depreciation	-9.42M	-15.68M	-24.34M	-32.29M	-39.93M
Net Property Plant And Equipment	54.7M	62.7M	53.26M	47.75M	37.09M
Long-term Investments	-	17.7M	-	-	-
Other Long-Term Assets, Total	4.13M	4.79M	5.68M	4.82M	4.25M
Total Assets	314M	279M	171M	120M	147M
Liabilities
Accounts Payable, Total	10.72M	9.58M	5.63M	5.16M	3.58M
Accrued Expenses, Total	6.03M	10M	12.21M	7.47M	8.38M
Current Portion of Leases	1.99M	4.01M	4.32M	2.78M	3.02M
Current Income Taxes Payable	-	-	-	348K	277K
Other Current Liabilities	3.02M	669K	573K	214K	176K
Total Current Liabilities	21.77M	24.25M	22.73M	15.98M	15.44M
Long-Term Leases	13.71M	11.09M	8.1M	10.83M	7.81M
Other Non Current Liabilities	182K	228K	253K	281K	410K
Total Liabilities	35.66M	35.57M	31.09M	27.09M	23.66M
Preferred Stock Convertible	-	-	-	-	-
Total Preferred Equity	-	-	-	-	-
Common Stock, Total	4K	7K	7K	8K	21K
Additional Paid In Capital	434M	523M	543M	607M	728M
Retained Earnings	-156M	-279M	-403M	-514M	-605M
Comprehensive Income and Other	-141K	-378K	-106K	28K	-
Total Common Equity	279M	243M	139M	92.85M	123M
Total Equity	279M	243M	139M	92.85M	123M
Total Liabilities And Equity	314M	279M	171M	120M	147M
Supplemental Items
ECS Total Shares Outstanding on Filing Date	41.29M	66.87M	78.52M	87.58M	217M
ECS Total Common Shares Outstanding	41.29M	66.86M	68.33M	86.54M	217M
Book Value / Share	6.75	3.64	2.04	1.07	0.57
Tangible Book Value	279M	243M	139M	92.85M	123M
Tangible Book Value Per Share	6.75	3.64	2.04	1.07	0.57
Total Debt	15.7M	15.1M	12.42M	13.61M	10.83M
Net Debt	-236M	-189M	-92.22M	-47.84M	-89.72M
Debt Equivalent Oper. Leases	45.6M	47M	45.01M	48.04M	39.83M
Account Code - Inventory Valuation	3	3	3	3	3
Machinery, Total	12.64M	39.98M	40.28M	40.07M	41.29M
Full Time Employees	106	141	140	97	70

Fiscal Period: December	2021	2022	2023	2024	2025
Net Income	-72.72M	-124M	-124M	-111M	-90.6M
Depreciation & Amortization - CF	2.96M	6.47M	8.69M	8.47M	8.44M
Depreciation & Amortization, Total	2.96M	6.47M	8.69M	8.47M	8.44M
(Gain) Loss From Sale Of Asset	61K	-	-	-	-
(Gain) Loss on Sale of Investments - (CF)	131K	-307K	315K	-184K	411K
Stock-Based Compensation (CF)	2.95M	11.47M	15.31M	16.5M	13.05M
Other Operating Activities, Total	1.06M	2.46M	3.35M	3.77M	2.9M
Change In Accounts Payable	8.6M	1.66M	-3.28M	-581K	-1.43M
Change in Other Net Operating Assets	-3.86M	-2.51M	-2.37M	-7.35M	-1.03M
Cash from Operations	-60.81M	-104M	-102M	-90.5M	-68.26M
Capital Expenditure	-25.12M	-20.63M	-1.24M	-1.02M	-618K
Investment in Marketable and Equity Securities, Total	-213M	104M	49.98M	2.14M	56.7M
Other Investing Activities, Total	-	8K	-25K	17K	-
Cash from Investing	-239M	83.65M	48.72M	1.13M	56.08M
Issuance of Common Stock	189M	77.77M	4.55M	47.75M	108M
Repurchase of Common Stock	-13K	-	-	-	-
Issuance of Preferred Stock	19.98M	-	-	-	-
Other Financing Activities, Total	-	-	-501K	-	-
Cash from Financing	209M	77.77M	4.05M	47.75M	108M
Net Change in Cash	-90.41M	57M	-49.31M	-41.62M	96.22M
Supplemental Items
Levered Free Cash Flow	-52.6M	-83.92M	-60.78M	-52.73M	-37.36M
Unlevered Free Cash Flow	-52.6M	-83.92M	-60.78M	-52.73M	-37.36M
Change In Net Working Capital	-12.11M	2.71M	1.54M	4.21M	-109K

Fiscal Period: December	2021	2022	2023	2024	2025
Profitability
Return on Assets	-19.68	-26.47	-36.49	-49.9	-43.72
Return on Total Capital	-20.99	-28.41	-39.97	-56.11	-48.5
Return On Equity %	-34.8	-47.39	-64.83	-95.69	-83.84
Return on Common Equity	-73.75	-47.39	-64.83	-95.69	-83.84
Short Term Liquidity
Current Ratio	11.73	7.99	4.91	4.22	6.84
Quick Ratio	11.54	7.69	4.6	3.85	6.51
Operating Cash Flow to Current Liabilities	-2.79	-4.31	-4.49	-5.67	-4.42
Long Term Solvency
Total Debt/Equity	5.64	6.2	8.91	14.66	8.79
Total Debt / Total Capital	5.34	5.84	8.18	12.78	8.08
LT Debt/Equity	4.92	4.56	5.81	11.66	6.34
Long-Term Debt / Total Capital	4.66	4.29	5.34	10.17	5.82
Total Liabilities / Total Assets	11.35	12.75	18.23	22.58	16.1
Total Debt / EBITDA	-0.24	-0.13	-0.11	-0.13	-0.14
Net Debt / EBITDA	3.67	1.67	0.79	0.47	1.12
Total Debt / (EBITDA - Capex)	-0.18	-0.11	-0.11	-0.13	-0.13
Net Debt / (EBITDA - Capex)	2.64	1.41	0.78	0.47	1.11
Growth Over Prior Year
EBITDA, 1 Yr. Growth %	91.73	70.6	2.81	-12.27	-21.01
EBITA, 1 Yr. Growth %	87.1	72.54	4.44	-11.62	-19.51
EBIT, 1 Yr. Growth %	87.1	72.54	4.44	-11.62	-19.51
Earnings From Cont. Operations, 1 Yr. Growth %	89.4	70.05	0.34	-10.44	-18.48
Net Income, 1 Yr. Growth %	89.4	70.05	0.34	-10.44	-18.48
Normalized Net Income, 1 Yr. Growth %	89.04	70.05	0.34	-10.44	-18.48
Diluted EPS Before Extra, 1 Yr. Growth %	-89.62	-32.72	-39.05	-22.09	-54.8
Net Property, Plant and Equip., 1 Yr. Growth %	218.33	14.61	-15.06	-10.34	-22.32
Total Assets, 1 Yr. Growth %	112.06	-11.22	-38.87	-29.66	22.5
Tangible Book Value, 1 Yr. Growth %	-442.53	-12.62	-42.71	-33.4	32.75
Common Equity, 1 Yr. Growth %	-442.53	-12.62	-42.71	-33.4	32.75
Cash From Operations, 1 Yr. Growth %	71.56	71.72	-2.25	-11.34	-24.57
Capital Expenditures, 1 Yr. Growth %	157.31	-17.88	-93.99	-17.27	-39.71
Levered Free Cash Flow, 1 Yr. Growth %	73.9	59.52	-27.57	-13.25	-29.15
Unlevered Free Cash Flow, 1 Yr. Growth %	73.9	59.52	-27.57	-13.25	-29.15
Compound Annual Growth Rate Over Two Years
EBITDA, 2 Yr. CAGR %	64.78	80.86	32.44	-5.02	-16.75
EBITA, 2 Yr. CAGR %	62.09	79.68	34.24	-3.93	-15.66
EBIT, 2 Yr. CAGR %	62.09	79.68	34.24	-3.93	-15.66
Earnings From Cont. Operations, 2 Yr. CAGR %	66.5	79.47	30.63	-5.2	-14.55
Net Income, 2 Yr. CAGR %	66.5	79.47	30.63	-5.2	-14.55
Normalized Net Income, 2 Yr. CAGR %	66.44	79.37	30.63	-5.2	-14.55
Diluted EPS Before Extra, 2 Yr. CAGR %	-65.63	-73.57	-35.96	-31.09	-40.66
Net Property, Plant and Equip., 2 Yr. CAGR %	139.03	91	-1.33	-12.73	-16.55
Total Assets, 2 Yr. CAGR %	187.54	37.21	-26.33	-34.43	-7.18
Tangible Book Value, 2 Yr. CAGR %	152.35	73	-29.25	-38.23	-5.97
Common Equity, 2 Yr. CAGR %	152.35	73	-29.25	-38.23	-5.97
Cash From Operations, 2 Yr. CAGR %	58.86	71.64	29.56	-6.9	-18.22
Capital Expenditures, 2 Yr. CAGR %	193.01	45.36	-77.79	-77.71	-29.38
Levered Free Cash Flow, 2 Yr. CAGR %	-	66.56	7.49	-20.73	-21.6
Unlevered Free Cash Flow, 2 Yr. CAGR %	-	66.56	7.49	-20.73	-21.6
Compound Annual Growth Rate Over Three Years
EBITDA, 3 Yr. CAGR %	-	66.7	49.82	15.45	-10.68
EBITA, 3 Yr. CAGR %	-	65.5	49.95	16.78	-9.43
EBIT, 3 Yr. CAGR %	-	65.5	49.95	16.78	-9.43
Earnings From Cont. Operations, 3 Yr. CAGR %	-	67.68	47.85	15.18	-9.85
Net Income, 3 Yr. CAGR %	-	67.68	47.85	15.18	-9.85
Normalized Net Income, 3 Yr. CAGR %	-	67.68	47.79	15.18	-9.85
Diluted EPS Before Extra, 3 Yr. CAGR %	-	-57	-65.08	-31.64	-40.12
Net Property, Plant and Equip., 3 Yr. CAGR %	-	87.08	45.79	-4.43	-16.05
Total Assets, 3 Yr. CAGR %	-	94.35	4.8	-27.46	-19.24
Tangible Book Value, 3 Yr. CAGR %	-	77.2	19.69	-30.66	-20.29
Common Equity, 3 Yr. CAGR %	-	77.2	19.69	-30.66	-20.29
Cash From Operations, 3 Yr. CAGR %	-	63.04	42.27	14.17	-13.21
Capital Expenditures, 3 Yr. CAGR %	-	91.75	-49.75	-65.57	-68.94
Levered Free Cash Flow, 3 Yr. CAGR %	-	-	26.19	0.08	-23.64
Unlevered Free Cash Flow, 3 Yr. CAGR %	-	-	26.19	0.08	-23.64
Compound Annual Growth Rate Over Five Years
EBITDA, 5 Yr. CAGR %	-	-	-	33.11	18.44
EBITA, 5 Yr. CAGR %	-	-	-	33.14	19.12
EBIT, 5 Yr. CAGR %	-	-	-	33.14	19.12
Earnings From Cont. Operations, 5 Yr. CAGR %	-	-	-	33.48	18.73
Net Income, 5 Yr. CAGR %	-	-	-	33.48	18.73
Normalized Net Income, 5 Yr. CAGR %	-	-	-	33.48	18.71
Diluted EPS Before Extra, 5 Yr. CAGR %	-	-	-	-48.07	-56.83
Net Property, Plant and Equip., 5 Yr. CAGR %	-	-	-	37.9	16.63
Total Assets, 5 Yr. CAGR %	-	-	-	25.84	-0.17
Tangible Book Value, 5 Yr. CAGR %	-	-	-	16.25	8.68
Common Equity, 5 Yr. CAGR %	-	-	-	16.25	8.68
Cash From Operations, 5 Yr. CAGR %	-	-	-	30.3	14
Capital Expenditures, 5 Yr. CAGR %	-	-	-	-18.92	-42.42
Levered Free Cash Flow, 5 Yr. CAGR %	-	-	-	-	4.31
Unlevered Free Cash Flow, 5 Yr. CAGR %	-	-	-	-	4.31